Flexion Therapeutics

208 articles about Flexion Therapeutics

• Flexion Announces Presentation Of Results From Pivotal Phase IIb And Phase III Clinical Trials For Zilretta At Osteoarthritis Research Society International (OARSI) 2016 World Congress

  4/4/2016

• Flexion Reports Year-End 2015 Financial Results

  3/11/2016

• Flexion Rockets as Lead Drug Meets Primary Endpoint in Late Stage Study

  2/18/2016

• Flexion To Present At Oppenheimer 6th Annual Healthcare Conference

  12/4/2015

• Flexion Enrolls First Patient In Pharmacokinetic Study Of Zilretta For Osteoarthritis Of The Knee

  12/2/2015

• Flexion To Present At Stifel 2015 Healthcare Conference

  11/16/2015

• Flexion Reports Third-Quarter 2015 Financial Results

  11/10/2015

• Flexion To Report Third-Quarter 2015 Financial Results On November 9, 2015

  11/2/2015

• Flexion Tanks as Lead Drug Flunks Pivotal Phase IIb Clinical Trial

  9/10/2015

• Flexion Granted Fast Track Status By The FDA For FX006 For Treatment Of Osteoarthritis Of The Knee

  9/2/2015

• Flexion Reports Second-Quarter 2015 Financial Results

  8/7/2015

• Flexion Secures $30 Million In Debt Financing

  8/5/2015

• Flexion Expands Supply Capacity For FX006 By Entering Into Agreement With Patheon

  8/5/2015

• Flexion Completes Enrollment In Phase III Clinical Trial With Lead Compound FX006 In Patients With Osteoarthritis Of The Knee

  7/30/2015

• Flexion' Final FX006 Data From Completed Phase IIb Dose-Ranging Trial Published In Journal Of Bone And Joint Surgery

  6/4/2015

• Flexion Reports First-Quarter 2015 Financial Results

  5/8/2015

• Flexion To Report First-Quarter 2015 Financial Results On May 7, 2015

  5/1/2015

• Flexion Awarded Approximately $2 Million From U.S. Department Of Defense To Conduct Clinical Trial Of FX006 In Military Personnel With Osteoarthritis Of The Knee

  4/30/2015

• Flexion To Present At 14th Annual Needham Healthcare Conference

  4/8/2015

• Flexion CEO Discusses Pipeline and Jobs

  4/3/2015